*By Christian Smith*
After an overdose earlier this week, Demi Lovato's life was reportedly saved by Narcan, a nasal administrator of naloxone that counteracts the effects of opioids. When administered quicklyーthrough either nasal mist or injectionーnaloxone can temporarily halt an overdose, allowing EMTs enough time to respond. The medication is available without a prescription in 49 states, and the generic version costs about $20 per dose.
But all merits aside, is the drug's accessibility enabling addicts to push their limits?
Dr. Roger Crystal, the lead inventor of Narcan and CEO of Opiant Pharmaceuticals, says there's little evidence to support that concern.
"Addiction like any kind of chronic disease is something you can control using better medication, but ultimately you can't cure," Crystal told Cheddar. "To think about an opioid addict behaving rationally and saying, 'well because I have access to Narcan I'll shoot more heroin, inject more heroin' there's no proof for that whatsoever."
Naloxone is considered some of the best ammunition on the front lines of America's growing opioid epidemic. A reported 2 million Americans have an addition to opioidsーand the number isn't going down. U.S. Surgeon General Jerome Adams [issued an advisory](https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html) in April urging anyoneーand their close family and friendsーwho uses painkillers, heroin, fentanyl, or other opioids to carry naloxone in case of an emergency.
Crystal isn't stopping at Narcan: he told Cheddar he's also developing a heroin vaccine, suggesting the inventor has lofty ambitions for the future of overdose prevention.
Although Crystal may be aware of lingering ethical concerns, he doesn't think they dwarf his mission. After all, Lovato has him to thank.
"Putting it in the hands of everyone and anyone is critical," Crystal said.
For more on this story, [click here](https://cheddar.com/videos/how-one-pharmaceutical-company-is-fighting-the-opioid-epidemic).
Michael Simon, staff writer for PCWorld, discusses the Waymo vs. Uber trade secrets trial and the testimony from former Uber CEO Travis Kalanick.
After two straight days of sell-offs, the major indexes waffled on Wall Street Tuesday. Space X's Falcon Heavy launched into space Tuesday afternoon. Disney, Chipotle and Snap report earnings.
SpaceX has officially launched the Falcon Heavy. This is the world's most powerful rocket and the launch captivated many around the world.
This Changes Things: Advice for the executives and leaders of tomorrow, brought to you by American Express OPEN. On Between Bells: Falcon Heavy launch, Olympic preview, and more. With Bacardi, FHM, and Entrepreneur.
After years of anticipation, SpaceX is supposed to launch its first ever Falcon Heavy rocket today, but strong winds could put a dent in the company's plans. Mary Beth Griggs from Popular Science explains what's causing the delay.
The stock market seems to bounce back slightly following the biggest one-day drop ever recorded for the Dow and S&P 500. The Falcon Heavy is finally scheduled to launch today. Lululemon's CEO is resigning. Plus, it's our weekly trading show, The Long and the Short.
Hanneke Weitering, staff writer for Space.com, breaks down what could go wrong or right during SpaceX's Falcon Heavy launch. The company is planning on launching the rocket from the Kennedy Space Center Tuesday after years of delay.
Platterz uses artificial intelligence to make office catering easier. The tech platform just closed their Series A funding round and raised $15 million.
"The Bad Astronomer" Phil Plait discusses what makes SpaceX's highly-anticipated Falcon Heavy launch so complicated, and why it will be "spectacular," whatever happens.
Apple Music is on track to outpace Spotify in the U.S. We dive into what's behind the latest ups and downs in the stock market. Sean Black, co-founder and CEO of Knock, tells Cheddar about his plans to take his company public in 2020. Plus, we break down the Super Bowl advertising wins and losses.
